Uterine Fibroids – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Uterine leiomyomas, commonly referred to as fibroids or myomas, are noncancerous tumors primarily affecting women of reproductive age. Tumors arise from the smooth muscle cells of the uterus, specifically the myometrium. While the exact cause of uterine fibroids is not fully understood, it has been suggested that ovarian hormones may play a crucial role in their development. Uterine fibroids are classified based on location; the three types are subserosal (projecting outside the uterus), intramural (within the myometrium), and submucosal (projecting into the uterine cavity). Symptoms associated with these tumors may include irregular or excessive bleeding leading to anemia, pelvic pain or pressure, bowel and bladder dysfunction, pain during sexual intercourse, infertility, and recurrent miscarriage. These tumors may result in complications such as chronic pelvic pain, heavy menstrual bleeding, poor pregnancy outcomes, infertility, constipation, urinary tract infections, and urinary incontinence. Women with fibroids are at a higher risk of postpartum hemorrhage due to an increased risk of uterine atony during the postpartum period. Increasing age and African descent are the primary risk factors associated with the development of fibroids.
- The prevalence of leiomyosarcoma is estimated at one in 400 (0.25%) women undergoing surgery for fibroids.
Thelansis’s “Uterine Fibroids Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uterine Fibroids treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Uterine Fibroids across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Uterine Fibroids Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment